Ask Lazlo

life sciences… only

Calistoga Pharmaceuticals

In Frazier Healthcare Ventures portfolio

News: Lead drug CAL-101 is said to kill tumor cells (Dec. 9, 2008)

Advertisements

December 15, 2008 Posted by | Companies | , , | Leave a comment

So, VC’s Broke… Can We Fix It?

There was a terrific interview with Alan Frazier (from Frazier Healthcare Ventures) posted on Xconomy’s site.  I encourage everyone to check it out.  

Here’s the major passage I took away (quoting Mr. Frazier):

We are investing a little more than half in biotech, and the balance in medical devices. We are, for sure, doing less startups and more later-stage companies. We do a lot of new companies, still, probably one-fourth of our companies are new companies. But a lot of them are like Calistoga where it starts out with a product pretty much ready to go, where we pull it from someone else and try it in a new indication.

So, it seems to me like there is a new equation for VC that looks a lot more like private equity.  In other words, VC’s will be looking for enterprises in the future that are closer to positive cash flow, and they will be looking for companies that will make attractive acquisition targets (as opposed to potential IPOs).

December 8, 2008 Posted by | Biotech, Deals, Med Tech, Pharma | , , , , , , , | Leave a comment

Seattle Genetics

Seattle GeneticsSGN-35.  Targeted antibody that identifies CD-30 and dumps a lethal dose of chemotherapy into tumor cells.

December 6, 2008 Posted by | Biotech, Companies | , , , , | Leave a comment

Robert Nelsen: ARCH Venture Partners, Managing Director

Robert NelsenCompany: Arch Venture Partners

Position: Co-founder and Managing Director

Bio (from http://www.archventure.com/directors.html)

Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners.

Mr. Nelsen joined ARCH at its founding and has played a significant role in the early sourcing, financing and development of more than thirty companies including Sapphire Energy, Ikaria, Illumina (ILMN), Adolor (ADLR), Aviron (AVIR, acquired by Medimmune-MEDI), Caliper Life Sciences (CALP), Trubion Pharmaceuticals (TRBN), Array BioPharma (ARRY), NetBot, deCODE Genetics (DCGN), Nanosys, Alnylam Pharmaceuticals (ALNY), XenoPort (XNPT), GenVec (GNVC), R2 Technology (acquired by Hologic-HOLX), IDUN Pharmaceuticals (acquired by Pfizer-PFE), Genomica (GNOM, acquired by Exelixis-EXEL), Surface Logix, NeurogesX (NGSX), Classmates.com (acquired by United Online-UNTD), Nura (acquired by Omeros), Kythera Biopharmaceuticals, Elixir Pharmaceuticals, Spaltudaq, VLST, Ensemble Discovery, Accelerator, Apoptos, Fate Therapeutics, Agios Pharmaceuticals, and Everyday Learning.

Mr. Nelsen is a director of Ikaria, Sapphire Energy, Fate Therapeutics, Agios Pharmaceuticals, NeurogesX, and Kythera Biopharmaceuticals. He previously serves on the boards of Trubion Pharmaceuticals, Surface Logix, Adolor, NetBot, Everyday Learning, Spaltudaq, Array BioPharma, Caliper Life Sciences, Illumina, R2 Technology, and Classmates.com, among others. He also serves as a director of the Fred Hutchinson Cancer Research Institute. Mr. Nelsen holds an M.B.A. from The University of Chicago and a B.S. in Economics and Biology from the University of Puget Sound.

November 28, 2008 Posted by | Profiles, Venture Capital | , , , , | Leave a comment